Wednesday, August 26, 2026

 

Clues to longevity may reside in the genomes of long-lived bats



Scientists are finding that bat genes involved in viral interactions also play a role in longevity



University of California - Berkeley

Longeared bat 

image: 

This longeared bat, Myotis evotis, was captured in Arizona by researchers from UC Berkeley and the University of Arizona. The scientists took tissue samples from the wings before releasing it and used the samples to sequence the bat's genome and to establish cell cultures for study.

view more 

Credit: Elise Lauterbur





The secret to a long life may lie in the genomes of the longest-lived mammals for their size: bats.

That idea captivated Juan Manuel Vazquez when he was a graduate student at the University of Chicago, but at the time he couldn’t find any good, published information on bat genomes to provide clues. Once he became a UC Berkeley postdoctoral fellow in 2020, however, he unleashed his passion and began scouring the Western U.S. for bat species that could provide tissue samples and DNA to sequence.

Enlisting the help of Berkeley undergraduates, he traveled around the West erecting mist nets over streams, ponds and rivers at night to capture, biopsy and release as many species of bats as he could. He focused on those in the genus Myotis, which contains the bat with the longest lifetime — a Brandt’s myotis, Myotis brandtii. One individual was banded in Europe and recaptured 50 years later.

In a new paper appearing this week in the journal Nature, Vazquez and colleagues report the first analysis of eight Myotis genomes and the discovery of a close link between the animal’s longevity and its immune system — longer-lived bats had higher levels of cancer-fighting genes.

The findings suggest that an immune system able to mount an overwhelming attack against infectious organisms and cancer may be integral to a long lifespan. The overlap between genes involved in aging and those involved in fighting disease also means that understanding one will help scientists understand the other.

“Bats evolved to live for a long time without getting diseases, which suggests that we don't necessarily need to look at diseases of aging and diseases of infection as completely separate fields,” Vazquez said. “We can look at these bats and try to understand how, in the same way you can improve your immune system to fight off viruses, maybe you can improve your immune system so it doesn't decline in old age. Or maybe bats can help us find ways to fight off tumors so our immune system doesn’t get tired, and that can also help us deal with other stresses of life and not exhaust our immunity.”

For the study, Vazquez cultured cells he biopsied from the wings of the bats. (He currently has cell cultures from 259 individuals representing 32 species.) When he treated cultured bat cells with toxic chemicals, he found an unusual response: for the longest-lived bat in his sample, the widespread little brown bat (Myotis lucifugus), the toxin didn’t trigger activation of genes for DNA repair proteins, but rather up-regulated genes promoting cell death.

“We found the literal opposite of what we expected if you treat the bats with a lethal dose of this chemical,” he said. “The longest-lived bat in North America decides ‘I can't save this ship’ and immediately switches gears to prioritize killing off the cells that are damaged. The elephant, another cancer-resistant species that is long-lived, has the exact same strategy — if you can't save the cell, kill the cell.”

The discovery is a heads-up that clues to longevity can be gleaned from understanding the different ways animals deal with disease, said Peter Sudmant, a Berkeley associate professor of integrative biology who studies the genes involved in aging and longevity.

“By looking across the diversity of life and the remarkable longevities of different species, we hope we can better understand the interplay between DNA damage and the immune system to enable us to have full and healthy life spans,” he said.

“If you start looking at long-lived species like elephants, whales and bats, you start finding ways that nature has actually already resolved a lot of these problems in human health,” Vazquez added.

Longevity, an active lifestyle and an immune system on high alert

The bat lifestyle has been a big success since the group arose about 60 million years ago. Bats now comprise 20% of all mammalian species, live on all continents except Antarctica and occupy a wide range of ecological niches. Of the known 1,511 species, about 139 are in the Myotis genus, which is known for bats exhibiting an extreme range of lifespans. While Brandt’s myotis bats can live half a century, the black Myotis — Myotis nigricans, of South and Central America — lives a mere seven years. This is as if our close relative, Homo neanderthalensis, lived nine times longer than modern Homo sapiens, Vazquez said.

Despite bats’ evolutionary success, scientists were surprised to find that their immune systems are hyperactive, working overtime to suppress damaging inflammation from constant viral infections without actually becoming sick. As a result, healthy bats can host an amazing variety of viruses, some of which, like the cause of COVID-19, can spill over into human populations.

Some researchers have linked bats’ robust immune systems to their very active lifestyle. Vazquez likens bats’ nighttime patrols for bugs to running several ultramarathons every day.

“Bats have evolved this incredible fitness capacity, this incredible ability to deal with disease and this incredible ability to be able to prevent cancer,” he said. “That means that, by understanding how bats have evolved to do all these things that other mammals haven't, we can find completely new and unexpected ways of dealing with the normal things that cause human diseases.”

The new study provides tantalizing clues. Vazquez found that whenever he identified a bat gene linked to lifespan, his collaborator, Elise Lauterbur, then at the University of Arizona, had identified the same gene as one involved in the bat’s interaction with viruses.

“There is way more overlap than you would expect just by random chance between the genes that are associated with longevity and genes that are associated with viral interactions,” he said.

Another surprise was that Myotis bats have an enhanced abundance of genes that make proteins that interact with DNA viruses — viruses, like herpes, that encode their genes using DNA. These proteins can either promote infection or protect against it, such as by boosting expression of the antiviral hormone interferon.

“DNA viral interacting proteins were strongly enriched for selection in bats in contrast to most other mammals, where there is a very strong enrichment for selection for both DNA and RNA viral interacting proteins,” Sudmant said. Humans and other primates, on the other hand, tend to have more genes for proteins that interact with RNA viruses, like COVID and HIV, than DNA viruses.

This mismatch between bats and humans may be why viruses spilling over from bats into humans and causing zoonotic disease have wreaked such havoc in recent years.

“Humans and bats are badly suited to each other,” Vazquez said. “That is one of the reasons why we have to be careful working with bats — it's a two-way street for zoonoses. We don't want to give the bat something and we don't want to get something from the bat. That mismatch is definitely something we should look into more.”

While Vazquez continues to investigate the genetic control of longevity in cell culture in his new faculty position at Pennsylvania State University, Sudmant is more interested in the immune responses of these cells.

“One thing that I'm really excited about is the trade-off between how a bat protects itself by producing proteins that attack the genomes of viruses but also protects its own genome from being attacked by those proteins,” he said.

He currently has cell cultures from many species of primate in which he is studying the genetic basis of longevity and how that’s related to DNA repair genes.

In addition to Vazquez, Sudmant and Lauterbur, now at the University of Vermont, other co-authors of the paper include Lucie Etienne of the École Normale Supérieure in Lyon, France, and David Enard of the University of Arizona in Tucson. The work was funded by the National Institutes of Health and the National Science Foundation.

 

Children of centenarians often live longer, develop some age-related diseases later



Largest study to date of centenarians’ offspring points to inherited biological factors beyond lifestyle as contributors to exceptional healthy aging




Albert Einstein College of Medicine

Sofiya Milman, M.D., M.S. Albert Einstein College of Medicine 

image: 

Sofiya Milman, M.D., M.S., professor of medicine and of genetics at Einstein, vice chair for research in the department of medicine, and senior author of the study.

view more 

Credit: Albert Einstein College of Medicine





(August 26, 2026—BRONX, NY)—Adults with at least one parent who reached age 100 lived longer and had substantially lower risks of cardiovascular disease and hypertension than people whose parents had shorter lifespans, according to a study published today in JAMA Network Open.

The study, led by researchers at Albert Einstein College of Medicine, Boston University, and Tufts Medical Center, adds to evidence that exceptional longevity and healthy aging run in families and suggests that inherited biological factors may help explain those advantages beyond lifestyle.  

“Centenarians—people who live to age 100 or older—offer crucial insights into what it looks like to age well,” said Sofiya Milman, M.D., M.S., professor of medicine and of genetics at Einstein, vice chair for research in the department of medicine, and senior author of the study. “We wanted to know whether they pass their good health and longevity down to their children—and, if so, whether those advantages can be explained by healthy habits or whether something more fundamental, like genetics, is at work.”

Examining Existing Studies
Dr. Milman and colleagues analyzed data from three geographically diverse, long-running studies—the Einstein-led LonGenity study, the New England Centenarian Study (NECS) at Boston University, and the UK Biobank. A total of 2,319 centenarians’ offspring were compared with 2,703 controls. Centenarians’ offspring had at least one parent who reached age 100, while parents of control participants lived to age 85 or younger or were spouses of centenarians’ offspring.

The data spanned 16 years for LonGenity and the UK Biobank and 29 years for NECS. Although the three studies collected their data independently, the researchers used the same approach to compare participants’ risks of death and age-related diseases and determine whether the findings were consistent across all three groups.

Discovering Strikingly Similar Results
The researchers found that the health advantages associated with exceptional parental longevity remained largely consistent after accounting for lifestyle factors, including smoking, alcohol use, exercise, and diet, as well as education and socioeconomic status.

Compared with people whose parents had shorter lifespans, centenarians’ offspring at any given age had a 42% lower risk of death, a 33% lower risk of cardiovascular disease, and a 32% lower risk of hypertension.

In addition, these outcomes tended to occur later in life among centenarians’ offspring: on average, death occurred about three years later and hypertension about five years later. Having a centenarian parent did not clearly confer protection with respect to stroke (risk was reduced only in the LonGenity and NECS studies) and cancer (centenarians’ offspring were no less likely to develop cancer, a finding consistent with some previous studies).

“The overall consistency of these findings across these quite different studies was especially noteworthy and reinforces the idea that exceptional longevity runs in families,” said Eric Reed, Ph.D., staff scientist in medicine, and lead author of the study. “This is not to say that lifestyle doesn’t count—healthy behaviors remain important for everyone. But some people from families with exceptional longevity appear to enjoy biological advantages that help them remain healthy despite the environmental and behavioral factors that affect us all.”

A Window into Healthy Aging
“This study wasn’t designed to identify the specific inherited traits that benefit centenarians’ children,” Dr. Milman said. “However, studying families with exceptional longevity can provide a unique window into the biology of healthy aging. Our findings provide a strong rationale for studying centenarians and their families to uncover those biological factors that promote longevity and protect these individuals from age-related diseases.

“Ultimately,” Dr. Milman added, “discovering those factors could lead to treatments that mimic the effects of naturally occurring longevity mechanisms, potentially helping people who did not inherit exceptional longevity to live longer and healthier lives.”

“This study provides strong evidence that the offspring of centenarians share some of their parents’ advantages in healthy aging,” said study co-author Paola Sebastiani, Ph.D., director of the Center for Quantitative Methods and Data Science at Tufts Medical Center. “These findings bring us closer to understanding the biological factors that may help protect against age-related disease and promote longer, healthier lives.”

Additional Einstein authors include Matthew Wysocki, M.D., and authors Maya Gal, B.A., Sandra Aleksic, M.D., Tina Gao, M.P.H., Kenny Ye, Ph.D., and Anna E. Bortnick, M.D., Ph.D. Other authors were Stacy Andersen, Ph.D., and Thomas Perls, M.D., of Boston University.

The paper, “Association of Parental Exceptional Longevity with Onset of Morbidity and Mortality Across Cohorts” (DOI: 10.1001/jamanetworkopen.2026.30964) was supported by NIH grants R01AG044829, R01AG061155, R01AG088659, U19AG023122, UH2AG064704, K23HL146982 and K76AG083274, as well as the Resnick Emerging Scholars in Aging award.

About Albert Einstein College of Medicine
Albert Einstein College of Medicine is one of the nation’s premier academic centers for basic science research, clinical investigation, and biomedical education. Located in the Bronx, Einstein is home to nearly 1,000 M.D., Ph.D., and M.D./Ph.D. students and more than 2,000 full-time faculty members. Einstein receives approximately $200M in funding from the National Institutes of Health (NIH) each year and houses six NIH-funded research centers, in cancer, intellectual and developmental disabilities, clinical and translational research, AIDS, and two in diabetes. In partnership with Montefiore Health System, Einstein advances clinical and translational research to accelerate the pace at which new discoveries become the treatments that benefit patients. For more information, please visit einsteinmed.edu, and follow us on  Instagram, LinkedIn, Twitter, Facebook, and view us on YouTube

 

 

Simple urine test could improve kidney transplant decisions and save hundreds more donor kidneys each year, study suggests



A new study finds donor urinary biomarkers significantly improve prediction of transplant success beyond current assessment methods




Johns Hopkins Medicine






A new study led by researchers at Johns Hopkins Medicine found that a simple urine test performed on deceased kidney donors could help doctors make better transplant decisions, giving more people access to successful kidney transplants while reducing the number of deceased donor kidneys that go unused.

Published in the Journal of the American Society of Nephrology, the study results show that testing donor kidney urine for three urinary biomarkers along with the widely used Kidney Donor Profile Index (KDPI) provides a substantially more accurate assessment of donor kidney quality than the KDPI alone.

According to the American Kidney Fund, more than 92,000 people in the United States are currently waiting for a kidney transplant, while nearly one in four recovered donor kidneys goes unused each year because clinicians are uncertain about organ quality. Existing organ allocation decisions rely heavily on the KDPI, which estimates donor risk primarily from deceased donors’ age and medical history, but has long been seen to offer only modest ability to predict successful transplantation.

The researchers say their study demonstrated that biomarker-enhanced assessment could provide transplant teams with greater confidence when evaluating kidneys that might otherwise be rejected.

The multicenter observational study evaluated deceased kidney donors enrolled between 2010 and 2013 through five organ procurement organizations. Researchers followed paired kidney transplant recipients for three years after transplantation to determine whether combining urinary biomarkers with the Kidney Donor Profile Index could improve prediction of long-term graft function.

Researchers analyzed 474 deceased kidney donors whose kidneys were transplanted into two separate recipients. By evaluating paired recipient outcomes, investigators were able to more precisely determine how donor kidney quality influenced long-term transplant success.

The study found that adding three urinary biomarkers—uromodulin, osteopontin, and YKL-40—to the KDPI improved the ability to predict which donated kidneys were more likely to have good long-term function. The accuracy of the prediction increased from 80% with the KDPI alone to 86% when the biomarkers were included. The approach also improved the identification of kidneys likely to have favorable outcomes by 10 percentage points while maintaining a specificity of 78%.

“We have been evaluating donor kidneys almost entirely on the donor’s history; their age, their diagnoses, a single creatinine value,” says Chirag R. Parikh, M.D., Ph.D., director of the Division of Nephrology at the Johns Hopkins University School of Medicine and senior author of the study. Creatinine is a waste product filtered out by the kidneys.  “These biomarkers tell us something the KDPI cannot: whether the kidney itself is repairing. That turns out to be a far better predictor of how it will work in a patient.”

Importantly, the researchers say, the three biomarkers can be measured using inexpensive urinary flow devices similar to at-home pregnancy tests. These point-of-care tests produce results within 30 minutes, making them practical for use during the fast-paced organ procurement process. The study demonstrated that the biomarker panel maintained strong predictive performance regardless of whether laboratory immunoassays or rapid lateral flow devices were used.

Using data from more than 1,500 deceased donors, researchers modeled how incorporating the three-biomarker panel into the kidney transplant evaluation process could improve clinical decision-making. Their analysis suggests that biomarker-guided assessments could also reduce unnecessary kidney biopsies in approximately 20% of donors and return at least one kidney to the transplant pool in about 7% of donors whose organs would otherwise not have been used.

To put these numbers into perspective, in a hypothetical group of 10,000 deceased donors, the researchers suggest this approach could eliminate more than 2,000 kidney biopsies and make approximately 700 additional kidneys available for transplantation. This would potentially expand access to life-saving transplants for patients waiting for a donor kidney.

Researchers say the findings, while observational and in need of further study, represent an important step toward precision medicine in kidney transplantation by incorporating real-time biological measures of organ health into existing allocation systems.

“Every kidney that is donated but not transplanted is a patient who stays on dialysis,” Parikh says. “If a test that is inexpensive and takes minutes can return even a portion of those organs to the pool, that matters enormously to the people who are waiting for a kidney transplant. Our next step is to prove it prospectively, in real time, at the point of donation.”

While more research is needed before the approach becomes standard practice, the findings suggest that adding urinary biomarkers to routine donor evaluations could lead to better transplant decisions, fewer non-utilized kidneys, and more life-saving transplants.

Study co-authors were from the University of Washington, Columbia University, Yale University, Vanderbilt University Medical Center, the University of Michigan, and CommonSpirit Health.

This research was supported by the National Institutes of Diabetes and Digestive and Kidney Disease (ROIDK-93770) and S. D’Souza: Edward S. Kraus Scholars Award.

Johns Hopkins University has filed a patent application related to the work described in this paper. The technology has been licensed to Eurofins for further development. The authors have disclosed this relationship in accordance with institutional and journal policies.

 

Common diabetes medication reduces preterm birth rates in high-risk pregnancies




Monash University






A common diabetes medication can reduce the risk of early and preterm births for mothers at high metabolic risk, according to new research led by Monash University.

Published in New England Journal of Medicine Evidence, the study investigated if metformin, a low-cost prescription, oral medication used to manage blood sugar, could help prevent gestational diabetes and other adverse pregnancy outcomes, including early birth. 

Gestational diabetes is characterised by elevated blood sugar during pregnancy and now affects one in five pregnant women in Australia. In severe cases, it can trigger premature labour. 

While metformin’s long-term impacts during pregnancy continue to be studied, researchers found metformin didn’t prevent gestational diabetes overall, but could offer significant protective benefits against premature delivery.

Preterm birth refers to delivery before 37 weeks, and remains a leading cause of mortality and morbidity for mothers and babies. In Australia, more than 26,000 babies (around 8 per cent of all births) are born prematurely each year, placing infants at risk of respiratory distress, developmental complications, and prolonged stays in neonatal intensive care.

Lead author, Associate Professor Aya Mousa,Head of Diabetes, Metabolic and Reproductive Health Research at the Monash Centre for Health Research & Implementation said women taking metformin had 35 per cent lower odds of giving birth prematurely (before 37 weeks) compared with those receiving a placebo.

“Metformin helps the body use insulin more effectively to lower blood sugar,” Associate Professor Mousa said. 

“We found women taking metformin had fewer births before 37 weeks. 

“This included halving the rate of births before 34 weeks - down to 2.2 per cent, compared with 4.4 per cent in the placebo group. 

“Among those who did deliver prematurely, pregnancy was prolonged by an average of 11 days for women on metformin.”

Researchers analysed individual patient data from seven randomised, placebo-controlled trials involving 2,297 pregnancies at high metabolic risk, including those with higher body weight, insulin resistance, or polyendocrine metabolic ovarian syndrome (PMOS, previously known as PCOS).

Associate Professor Mousa said metformin’s effect on preterm birth warranted further investigation.

“While these findings need to be confirmed in trials specifically designed to investigate preterm birth, including exploring optimal timing for starting metformin, they point to an important potential benefit that warrants further research,” Associate Professor Mousa said.

The study forms part of the Metformin in Pregnancy Study (MiPS), a large international collaboration led by Monash researchers, bringing together individual participant data from randomised trials in thousands of women, examining metformin use during pregnancy.

Senior author Professor Helena Teede, Director of the Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health, said the international collaboration helped address an important evidence gap around metformin use in pregnancy, with multiple further questions now being addressed using this vitally important data.

“Isolated studies have previously produced mixed findings and have not been large enough to definitively determine metformin effects including in preventing gestational diabetes,” Professor Teede said.

“By bringing together the original data from thousands of women across international trials, we could examine individual participants and account for differences such as age, body mass index, blood glucose levels and when treatment began, giving us a clearer picture of metformin’s effects during pregnancy.”

Metformin did not impact other pregnancy outcomes, including birth weight, high blood pressure, pre-eclampsia, induction of labour or Caesarean section.

The broader MiPS collaboration is also investigating the long-term outcomes of metformin exposure during pregnancy.